Current Infectious Disease Reports

, Volume 10, Issue 6, pp 466–472 | Cite as

Combination antifungal therapy: From bench to bedside

Article

Abstract

Invasive fungal infections are major causes of mortality in immunocompromised patients. Despite improved outcomes with new antifungals, there remains a pressing need to further improve outcomes, especially with invasive aspergillosis and other invasive mold infections. Combination antifungal therapy is an attractive option that offers the prospect for improved efficacy, decreased toxicity, reduced likelihood for the emergence of resistance, and shorter courses of therapy. The current available evidence regarding the role of combination antifungal therapy for invasive fungal infections is discussed in this article, including data from in vitro studies, animal models, and human clinical trials to try to clarify this important issue. Randomized, prospective clinical trials are urgently needed, especially for invasive aspergillosis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Eliopoulous GM: Synergism and antagonism. Infect Dis Clin North Am 1989, 3:399–406.Google Scholar
  2. 2.
    Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA: Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005, 18:163–194.PubMedCrossRefGoogle Scholar
  3. 3.
    Rex JH, Pfaller MA, Walsh TJ, et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001, 14:643–658.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis R, Diekema DJ, Messer SA, et al.: Comparison of E-test, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002, 49:345–351.PubMedCrossRefGoogle Scholar
  5. 5.
    Meletiadis J, Mouton JW, Meis JF, et al.: Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001, 39:3402–3408.PubMedCrossRefGoogle Scholar
  6. 6.
    Meletiadis J, Mouton JW, Meis JF, et al.: Comparison of spectrophotometric and visual reading of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H tetrazolium-hydroxide] for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001, 39:4256–4263.PubMedCrossRefGoogle Scholar
  7. 7.
    Klepser ME, Malone D, Lewis RE, et al.: Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000, 44:1917–1920.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693–715.PubMedCrossRefGoogle Scholar
  9. 9.
    Steinbach WJ: Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005, 5:203–210.PubMedCrossRefGoogle Scholar
  10. 10.
    Lewis RE: Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy 2006, 26:61S–67S.PubMedCrossRefGoogle Scholar
  11. 11.
    Fohrer C, Fornecker L, Nivoix Y, et al.: Antifungal combination treatment: a future perspective. Int J Antimicrob Agents 2006, 27(Suppl 1):25–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Kontoyiannis DP, Lewis RE: Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 2003, 6:257–269.PubMedCrossRefGoogle Scholar
  13. 13.
    Cuenca-Estrella M: Combinations of antifungal agents in therapy—what value are they? J Antimicrob Chemother 2004, 54:854–869.PubMedCrossRefGoogle Scholar
  14. 14.
    Pachl J, Suoboda P, Jacobs F, et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404–1413.PubMedCrossRefGoogle Scholar
  15. 15.
    Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834–1843.PubMedCrossRefGoogle Scholar
  16. 16.
    Kontoyiannis DP, Lewis RE: Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 2003, 6:257–269.PubMedCrossRefGoogle Scholar
  17. 17.
    Manavanthu EK, Alangaden GJ, Chandrasekar PH: Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003, 51:1423–1425.CrossRefGoogle Scholar
  18. 18.
    Arikan S, Lozano-Chiu M, Paetznick V, Rex JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245–247.PubMedCrossRefGoogle Scholar
  19. 19.
    Mosquera J, Sharp A, Moore CB, et al.: In vitro interaction of Terbinafine with itraconazole, fluconazole, amphotericin B, and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002, 50:189–194.PubMedCrossRefGoogle Scholar
  20. 20.
    Ryder NS, Leitner I: Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001, 39:91–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT: Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005, 49:4895–4902.PubMedCrossRefGoogle Scholar
  22. 22.
    Barchiesi F, Schimizzi AM, Caselli F, et al.: Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44:2435–2441.PubMedCrossRefGoogle Scholar
  23. 23.
    Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564–2568.PubMedCrossRefGoogle Scholar
  24. 24.
    Segal BH, Kwon-Chung J, Walsh TJ, et al.: Immunotherapy for fungal infections. Clin Infect Dis 2006, 42:507–515.PubMedCrossRefGoogle Scholar
  25. 25.
    Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS: Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agent Chemother 2005, 49:830–832.CrossRefGoogle Scholar
  26. 26.
    Ibrahim AS, Gebermariam T, Fu Y, et al.: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649–2657.PubMedCrossRefGoogle Scholar
  27. 27.
    Clemons KV, Stevens DA: Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis 2006, 19:360–364.PubMedCrossRefGoogle Scholar
  28. 28.
    Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole and placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221–1228.PubMedCrossRefGoogle Scholar
  29. 29.
    Rex JH, Walsh TJ, Sobel JD, et al.: Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000, 30:662–678.PubMedCrossRefGoogle Scholar
  30. 30.
    Lopez-Ciudad V, Castro-Orjales MJ, Leon C, et al.: Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006, 6:73.PubMedCrossRefGoogle Scholar
  31. 31.
    van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet 2004, 363:1764–1767.PubMedCrossRefGoogle Scholar
  33. 33.
    Verweij PE, Donnelly JP, Kullberg BJ, et al.: Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994, 22:81–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Kontoyiannis DP, Bodey GP, Hanna H, et al.: Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 2004, 45:139–141.PubMedCrossRefGoogle Scholar
  35. 35.
    Kontoyiannis DP, Hachem R, Lewis RE, et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292–299.PubMedCrossRefGoogle Scholar
  36. 36.
    Aliff TA, Masiak PG, Jurcic JG, et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003, 97:1025–1032.PubMedCrossRefGoogle Scholar
  37. 37.
    Kontoyiannias DP, Boktour M, Hanna H, et al.: Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005, 103:2334–2337.CrossRefGoogle Scholar
  38. 38.
    Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797–802.PubMedCrossRefGoogle Scholar
  39. 39.
    Marr KA, Boeckh M, Kim HW: Reply to Cesaro and Visintin. Clin Infect Dis 2005, 40:1075–1076.CrossRefGoogle Scholar
  40. 40.
    Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofugin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320–326.PubMedCrossRefGoogle Scholar
  41. 41.
    Vazquez L, Mateos JJ, Sanz-Rodriguez C, et al.: Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 2005, 90(Suppl):ECR39.PubMedGoogle Scholar
  42. 42.
    Van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective salvage therapy in zygomycosis: a retrospective study of 91 cases. Clin Infect Dis 2006, 42:e61–e65.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Division of Hematology/OncologyUniversity of Florida Shands Cancer CenterGainesvilleUSA

Personalised recommendations